Page last updated: 2024-10-14

bms-626529

Cross-References

ID SourceID
PubMed CID11317439
CHEMBL ID3301620
SCHEMBL ID760768
MeSH IDM0588682

Synonyms (46)

Synonym
1-(4-benzoylpiperazin-1-yl)-2-[4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl]ethane-1,2-dione
piperazine, 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-
HY-15440
bms-626529 ,
701213-36-7
temsavir
CS-0938
temsavir [inn]
temsavir [mi]
temsavir [who-dd]
temsavir [usan]
S6625
CHEMBL3301620
piperazine, 1-benzoyl-4-((4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo(2,3-c)pyridin-3-yl)oxoacetyl)-
unii-4b6j53w8n3
4b6j53w8n3 ,
1,2-ethanedione, 1-(4-benzoyl-1-piperazinyl)-2-(4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo(2,3-c)pyridin-3-yl)-
temsavir [usan:inn]
bms 626529
SCHEMBL760768
1-(4-benzoylpiperazin-1-yl)-2-(4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione
temsavir (usan)
D10734
AC-30242
bms626529
AKOS025396462
C21558
DTXSID20462146
1-(4-benzoylpiperazin-1-yl)-2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl]ethane-1,2-dione
83j ,
1-[4-(benzenecarbonyl)piperazin-1-yl]-2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl]ethane-1,2-dione
mfcd22665723
NCGC00379018-02
temsavirbms-626529
FT-0720945
DB14675
AS-35292
BCP09613
bdbm50236759
SB19162
EX-A2034
Q27259369
temsavir (bms-626529)
1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
A866678
BDB21336

Pharmacokinetics

ExcerptReference
" Similarly, coadministration of BMS-663068 with RTV increased the BMS-626529 Cmax and AUCtau by 53% and 45%, respectively."( Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Bertz, R; Furlong, M; Hanna, GJ; Hruska, M; Hwang, C; Landry, IS; Shah, V; Zhu, L, 2015
)

Bioavailability

ExcerptReference
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
"Many lead compounds fail to reach clinical trials despite being potent because of low bioavailability attributed to their insufficient solubility making solubility a primary and crucial factor in early phase drug discovery."( Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Baidya, ATK; Das, B; Kumar, R; Mathew, AT; Yadav, AK, 2022
)

Dosage Studied

Coadministration of BMS-663068 with ATV/r increased the B MS-626529 maximum concentration in plasma. Exposure-response analyses showed a relationship between the loge-transformed concentration and HIV-1 RNA level.

ExcerptReference
" Compared with the results obtained by administration of BMS-663068 alone, coadministration of BMS-663068 with ATV/r increased the BMS-626529 maximum concentration in plasma (Cmax) and the area under the concentration-time curve in one dosing interval (AUCtau) by 68% and 54%, respectively."( Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Bertz, R; Furlong, M; Hanna, GJ; Hruska, M; Hwang, C; Landry, IS; Shah, V; Zhu, L, 2015
)
" Exposure-response analyses showed a relationship between the loge-transformed concentration at the end of a dosing interval (Ctau) normalized for the protein binding-adjusted BMS-626529 half-maximal (50%) inhibitory concentration (PBAIC50) and the change in the HIV-1 RNA level from the baseline level after 7 days of BMS-663068 monotherapy."( Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
Abu Tarif, M; Bertz, RJ; Boulton, DW; Hanna, GJ; Hruska, M; Joshi, S; Landry, I; Lataillade, M; Pitsiu, M; Sadler, BM; Zhu, L, 2016
)
" Additionally, we observe additive inhibitory activity against pseudotyped viruses when B#24 is dosed in competition with the clinically used non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz."( Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline.
Banerjee, S; Blakemore, PR; Brack-Werner, R; Herrmann, A; Loesgen, S; Milicevic Sephton, S; Neuhaus, GF; Overacker, RD; Strother, JA, 2019
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GVesicular stomatitis virusPotency15.09160.01238.964839.8107AID1645842
Interferon betaHomo sapiens (human)Potency15.09160.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency15.09160.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency15.09160.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency15.09160.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)32.50000.00011.774010.0000AID1505612; AID1716337
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)17.00000.00011.753610.0000AID1505609; AID1716343; AID1716344
Cytochrome P450 2C8Homo sapiens (human)IC50 (µMol)25.00000.00081.88487.9000AID1716339
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)32.50000.00002.015110.0000AID1505615; AID1716342
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)32.50000.00002.800510.0000AID1505614; AID1716340
Cytochrome P450 2B6Homo sapiens (human)IC50 (µMol)25.00000.00113.418610.0000AID1716338
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)32.50000.00002.398310.0000AID1505613; AID1716341
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)21.90000.00091.901410.0000AID1716345
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 Human immunodeficiency virus 1Kd0.00080.00080.00990.0190AID1505635
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (111)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2B6Homo sapiens (human)
steroid metabolic processCytochrome P450 2B6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2B6Homo sapiens (human)
cellular ketone metabolic processCytochrome P450 2B6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2B6Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (64)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 2B6Homo sapiens (human)
iron ion bindingCytochrome P450 2B6Homo sapiens (human)
testosterone 16-alpha-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
heme bindingCytochrome P450 2B6Homo sapiens (human)
testosterone 16-beta-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2B6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2B6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2B6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2B6Homo sapiens (human)
cytoplasmCytochrome P450 2B6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (171)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1716307Antiviral activity against clinical isolate HIV-1 93BR019 infected in human PBMC cells assessed as reduction in viral transmission to TZM-bl cells pretreated for 1 hr before viral transmission and further incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716314Antiviral activity against pseudovirus HIV-1 HXB-2 harboring Env L116P mutant infected in human U87.CD4.CXCR4 cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716308Antiviral activity against clinical isolate HIV-1 CMU02 infected in human PBMC cells assessed as reduction in viral transmission to TZM-bl cells pretreated for 1 hr before viral transmission and further incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1267284AUC(last) in rat at 5 mg/kg, po2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Inhibitors of HIV-1 attachment: The discovery and structure-activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore.
AID1716315Antiviral activity against pseudovirus HIV-1 HXB-2 harboring Env A204D mutant infected in human U87.CD4.CXCR4 cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716325Antiviral activity against pseudovirus HIV-1 HXB-2 harboring Env M475I mutant infected in human U87.CD4.CXCR4 cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1505625AUC in cynomolgus monkey at 5 mg/kg, po administered via gavage2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1454935Cytotoxicity against human HCT116 cells after 6 days by XTT assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1716297Antiviral activity against HIV-1 3B infected in human H9 cells assessed as reduction in viral transmission to TZM-bl cells incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1454966Antiviral activity against HIV-1 subtype F by p24 ELISA2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1267288Solubility of crystalline form of compound in 50 mM potassium phosphate buffer at pH 5.7 by UV-Vis HPLC analysis2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Inhibitors of HIV-1 attachment: The discovery and structure-activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore.
AID1716327Solubility in 2 % DMSO at pH 7.4 at 500 uM incubated for 90 mins in shaker by spectrophotometry2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1505623Total clearance in beagle dog at 1 mg/kg, iv2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1454946Oral bioavailability in rat dosed as suspension2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1454955Antiviral activity against HIV-1 Bal infected in human PM1 cells harboring CCR5 co-receptor after 4 to 6 days by p24 ELISA2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1454961Antiviral activity against HIV-1 89.6 infected in human PM1 cells harboring dual co-receptors after 4 to 6 days by p24 ELISA2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1442784Unbound fraction in human plasma at 5 uM by LC-MS/MS based equilibrium dialysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1241771Antiviral activity against CCR5-tropic HIV1 JRFL infected in human PM1 cells by monogram phenosense entry assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID1716320Antiviral activity against pseudovirus HIV-1 HXB-2 harboring Env N425K mutant infected in human U87.CD4.CXCR4 cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1505647Drug uptake in Sprague-Dawley rat plasma assessed as BMS-626529 level at 200 mg/kg, po after 3 hrs2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1716321Antiviral activity against pseudovirus HIV-1 HXB-2 harboring Env M426L mutant infected in human U87.CD4.CXCR4 cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1505645Drug uptake in Sprague-Dawley rat plasma assessed as BMS-626529 level at <= 25 mg/kg, po after 3 hrs2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1505653Activation of PXR (unknown origin)2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1442782Metabolic stability in human liver microsomes assessed as compound remaining at 45 mins in presence of NADPH by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1716340Inhibition of human liver microsome CYP2C9 using diclofenac as substrate incubated for 20 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716346Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 1 hr followed by complete medium addition and measured after 48 hrs by XTT assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1505624Oral bioavailability in cynomolgus monkey at 5 mg/kg administered via gavage2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1505601Permeability in human Caco2 cells2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1454931Cytotoxicity against HEK293 cells after 6 days by XTT assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1454936Cytotoxicity against human MCF7 cells after 6 days by XTT assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1454969Antiviral activity against HIV-1 isolate CRF02_AG by p24 ELISA2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1454917Cytotoxicity against MDBK cells after 6 days by XTT assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1505638Antiviral activity against recombinant pseudotyped HIV1 subtype C infected in human U87 cells expressing CD4/CCR5/CXCR4 by luciferase reporter gene assay2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1505636Antiviral activity against recombinant pseudotyped HIV1 subtype B infected in human U87 cells expressing CD4/CCR5/CXCR4 by luciferase reporter gene assay2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1716311Antiviral activity against clinical isolate HIV-1 BCF01 infected in human PBMC cells assessed as reduction in viral transmission to TZM-bl cells pretreated for 1 hr before viral transmission and further incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1442780Apparent permeability from basolateral to apical side in human Caco2 cells at 10 uM at pH 7.4 by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1454960Antiviral activity against HIV-1 RF infected in human MT2 cells harboring CXCR4 co-receptor after 4 to 6 days2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1505637Antiviral activity against recombinant pseudotyped HIV1 subtype A infected in human U87 cells expressing CD4/CCR5/CXCR4 by luciferase reporter gene assay2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1716342Inhibition of human liver microsome CYP2D6 using bufuralol as substrate incubated for 20 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1605163Antiviral activity against HIV1 HXB2 infected in human TZM-bl cells preincubated for 30 min followed by viral infection and measured after 3 days by luciferase based assay2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.
AID1716336Protein binding in human plasma assessed as unbound fraction at 5 uM by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1454965Antiviral activity against HIV-1 isolate CRF01_AE by p24 ELISA2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1505618Aqueous solubility of the compound at pH 12018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1454957Antiviral activity against HIV-1 NL4 - 3 infected in human MT2 cells harboring CXCR4 co-receptor after 4 to 6 days2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1716341Inhibition of human liver microsome CYP2C19 using mephenytoin as substrate incubated for 20 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1454930Cytotoxicity against human MT2 cells after 6 days by XTT assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1505611Protein binding in human plasma2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1454952Antiviral activity against HIV 1 isolate JRFL by single cycle infectivity assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1267275Cytotoxicity against human HeLa cells after 6 days by MTT assay2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Inhibitors of HIV-1 attachment: The discovery and structure-activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore.
AID1505652Binding affinity to HIV-1 JRFL gp120 assessed as half life for dissociation2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1267286Half life in rat at 5 mg/kg, po2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Inhibitors of HIV-1 attachment: The discovery and structure-activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore.
AID1605255Antiviral activity against HIV1-ADA infected in human MOLT4 cells assessed as inhibition in cell to cell HIV1 transmission to human TZM-bl acceptor cells incubated for 24 hrs by luciferase based assay2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.
AID1716339Inhibition of human liver microsome CYP2C8 using paclitaxel as substrate incubated for 20 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716309Antiviral activity against clinical isolate HIV-1 Ru132 infected in human PBMC cells assessed as reduction in viral transmission to TZM-bl cells pretreated for 1 hr before viral transmission and further incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1542655Antiviral activity against ENV pseudotyped HIV1 JFRL infected in human HeLa67 cells expressing CD4/CCR5/CXCR5 after 72 hrs by luciferase reporter gene assay2019Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11
A survey of core replacements in indole-based HIV-1 attachment inhibitors.
AID1552577Antiviral activity against HIV1 89.6 pseudovirus infected in human TZM-bl cells assessed as inhibition of viral infection at 20 nM measured after 48 hrs post infection by bright Glo-luciferase reporter gene assay relative to control2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline.
AID1542656Cytotoxicity against human MT2 cells assessed as decrease in cell viability2019Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11
A survey of core replacements in indole-based HIV-1 attachment inhibitors.
AID1454959Antiviral activity against HIV-1 3B infected in human MT2 cells harboring CXCR4 co-receptor after 4 to 6 days2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1716312Antiviral activity against clinical isolate HIV-1 BCF03 infected in human PBMC cells assessed as reduction in viral transmission to TZM-bl cells pretreated for 1 hr before viral transmission and further incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1505603Metabolic stability in rat liver microsomes assessed as parent compound remaining after 10 mins2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1295703Aqueous solubility of the compound at pH 4 to 82016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.
AID1552553Antiviral activity against HIV1 HXB2 pseudovirus infected in human TZM-bl cells assessed as inhibition of viral infection at 20 nM measured after 48 hrs post infection by bright Glo-luciferase reporter gene assay relative to control2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline.
AID1454962Antiviral activity against HIV-1 subtype A by p24 ELISA2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1454924Inhibition of [3H]BMS-488043 binding to HIV-1 isolate JRFL gp120 after 60 mins by scintillation counting method2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1505622AUC in beagle dog at 5 mg/kg, po2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1505609Inhibition of CYP3A4 (unknown origin)2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1454941Cytotoxicity against human PM1 cells after 6 days by XTT assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1442781Efflux ratio of permeability from basolateral to apical over apical to basolateral side in human Caco2 cells at 10 uM at pH 7.4 by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1716313Antiviral activity against pseudovirus HIV-1 HXB-2 harboring wild type Env infected in human U87.CD4.CXCR4 cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716316Antiviral activity against pseudovirus HIV-1 HXB-2 harboring Env S375H mutant infected in human U87.CD4.CXCR4 cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716301Antiviral activity against clinical isolate HIV-1 93RW034 infected in human PBMC cells assessed as reduction in viral transmission to TZM-bl cells pretreated for 1 hr before viral transmission and further incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1505626Total clearance in cynomolgus monkey at 1 mg/kg, iv2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1505617Aqueous solubility of the compound at pH 7.42018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1454967Antiviral activity against HIV-1 F1 by p24 ELISA2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1442778Aqueous solubility of the compound at 1 to 100 uM in PBS at pH 7.4 after 2 hrs by turbidimetric analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1505604Oral bioavailability in Sprague-Dawley rat at 5 mg/kg2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1716335Metabolic stability in human liver microsomes assessed as intrinsic clearance at 3 uM incubated for 120 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1505602Metabolic stability in human liver microsomes assessed as parent compound remaining after 10 mins2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1552576Antiviral activity against HIV1 YU2 pseudovirus infected in human TZM-bl cells assessed as inhibition of viral infection at 20 nM measured after 48 hrs post infection by bright Glo-luciferase reporter gene assay relative to control2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline.
AID1505641Oral bioavailability in cynomolgus monkey assessed as BMS-626529 formation at 5 mg/kg administered via gavage2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1716323Antiviral activity against pseudovirus HIV-1 HXB-2 harboring Env F468L mutant infected in human U87.CD4.CXCR4 cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1454963Antiviral activity against HIV-1 subtype B by p24 ELISA2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1716318Antiviral activity against pseudovirus HIV-1 HXB-2 harboring Env S375Y mutant infected in human U87.CD4.CXCR4 cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716345Inhibition of human ERG transfected in HEK293 cells assessed as reduction in channel current at -80 mV holding potential by whole-cell patch clamp method2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716328Apparent permeability across apical to basolateral side in human Caco2 cells incubated for 2 hrs by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1505612Inhibition of CYP1A2 (unknown origin)2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1716334Metabolic stability in human liver microsomes assessed as parent compound remaining at 3 uM incubated for 120 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1454956Antiviral activity against HIV-1 LAI infected in human MT2 cells harboring CXCR4 co-receptor after 4 to 6 days2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1454911Inhibition of [3H]BMS-488043 binding to HIV-1 isolate JRFL gp120 assessed as dissociation half life incubated for 60 mins followed by CD4 addition by scintillation counting method2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1716319Antiviral activity against pseudovirus HIV-1 HXB-2 harboring Env I424F mutant infected in human U87.CD4.CXCR4 cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1241772Antiviral activity against CCR5-tropic HIV1 SF162 infected in human PM1 cells by monogram phenosense entry assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID1505608Half life in Sprague-Dawley rat at 1 mg/kg, iv2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1241768Antiviral activity against CXCR4-tropic HIV1 NL4-3 infected in human MT2 cells by monogram phenosense entry assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID1716338Inhibition of human liver microsome CYP2B6 using bupropion as substrate incubated for 20 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1442779Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM at pH 7.4 by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1716331Apparent permeability across apical to basolateral side in human Caco2 cells in presence of verapamil incubated for 2 hrs by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1442785Inhibition of CYP2C19 in human liver microsomes using mephenytoin as substrate after 60 mins in presence of NADPH by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1716326Solubility in 5% DMSO at pH 7.4 at 500 uM incubated for 90 mins in shaker by spectrophotometry2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1454954Antiviral activity against HIV-1 SF-162 infected in human PM1 cells harboring CCR5 co-receptor after 4 to 6 days by p24 ELISA2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1505621Oral bioavailability in beagle dog at 5 mg/kg2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1454953Antiviral activity against HIV-1 JR-FL infected in human PM1 cells harboring CCR5 co-receptor after 4 to 6 days by p24 ELISA2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1454923Competitive inhibition of soluble CD4 binding to HIV-1 gp120 after 2 hrs by ELISA2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1716317Antiviral activity against pseudovirus HIV-1 HXB-2 harboring Env S375W mutant infected in human U87.CD4.CXCR4 cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1505619Aqueous solubility of the compound at pH 102018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1716310Antiviral activity against clinical isolate HIV-1 RU570 infected in human PBMC cells assessed as reduction in viral transmission to TZM-bl cells pretreated for 1 hr before viral transmission and further incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716302Antiviral activity against Laboratory adapted HIV-1 LA1 infected in human PBMC cells assessed as reduction in viral transmission to TZM-bl cells pretreated for 1 hr before viral transmission and further incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716305Antiviral activity against clinical isolate HIV-1 92US073 infected in human PBMC cells assessed as reduction in viral transmission to TZM-bl cells pretreated for 1 hr before viral transmission and further incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1442790Inhibition of human ERG expressed in CHO cells by patch clamp electrophysiology assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1605164Cytotoxicity against human TZM-bl cells incubated for 3 days by MTS assay2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.
AID1716344Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 20 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1241770Antiviral activity against CXCR4-tropic HIV1 3B infected in human MT2 cells by monogram phenosense entry assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID1505651Selectivity ratio of EC50 for ENV pseudotyped CCR5-tropic HIV1 JFRL in presence of 40%human serum to EC50 for ENV pseudotyped CCR5-tropic HIV1 JFRL in absence of 40%human serum2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1241773Antiviral activity against CCR5-tropic HIV1 BAL infected in human PM1 cells by monogram phenosense entry assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID1267277Metabolic stability in rat liver microsomes assessed as compound remaining at 3 uM after 10 mins at pH 7.4 by LC/MS analysis2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Inhibitors of HIV-1 attachment: The discovery and structure-activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore.
AID1442783Intrinsic clearance in human liver microsomes assessed per mg protein in presence of NADPH by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1267285Cmax in rat at 5 mg/kg, po2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Inhibitors of HIV-1 attachment: The discovery and structure-activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore.
AID1442787Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate after 5 mins in presence of NADPH by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1454939Cytotoxicity against human NCI-H292 cells after 6 days by XTT assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1454934Cytotoxicity against human HeLa cells after 6 days by XTT assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1505640Oral bioavailability in beagle dog assessed as BMS-626529 formation at 5 mg/kg2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1454968Antiviral activity against HIV-1 isolate CRF_BF by p24 ELISA2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1454933Cytotoxicity against human HepG2 cells after 6 days by XTT assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1716337Inhibition of human liver microsome CYP1A2 using phenacetin as substrate incubated for 20 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1241767Antiviral activity against CXCR4-tropic HIV1 LAI infected in human MT2 cells by monogram phenosense entry assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID1505606Clearance in Sprague-Dawley rat at 1 mg/kg, iv2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1505639Oral bioavailability in Sprague-Dawley rat assessed as BMS-626529 formation at 5 mg/kg2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1505610Efflux ratio of permeability in human Caco2 cells2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1454926Aqueous solubility of the compound at pH 2 to 92018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1605254Antiviral activity against HIV1-3B infected in human H9 cells assessed as inhibition in cell to cell HIV1 transmission to human TZM-bl acceptor cells incubated for 24 hrs by luciferase based assay2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.
AID1716343Inhibition of human liver microsome CYP3A4 using testosterone as substrate incubated for 20 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716333Efflux ratio for apparent permeability across basolateral to apical side to apical to basolateral side in human Caco2 cells in presence of verapamil incubated for 2 hrs by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716324Antiviral activity against pseudovirus HIV-1 HXB-2 harboring Env M434I/I595F double mutant infected in human U87.CD4.CXCR4 cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1505598Cytotoxicity against human MT2 cells assessed as decrease in cell viability after 3 days by XTT assay2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1716304Antiviral activity against Laboratory adapted HIV-1 BaL infected in human PBMC cells assessed as reduction in viral transmission to TZM-bl cells pretreated for 1 hr before viral transmission and further incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716303Antiviral activity against Laboratory adapted HIV-1 89.6 infected in human PBMC cells assessed as reduction in viral transmission to TZM-bl cells pretreated for 1 hr before viral transmission and further incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716299Antiviral activity against HIV-1 ADA infected in human MOLT-4 cells assessed as reduction in viral transmission to TZM-bl cells incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1716300Antiviral activity against clinical isolate HIV-1 93RW018 infected in human PBMC cells assessed as reduction in viral transmission to TZM-bl cells pretreated for 1 hr before viral transmission and further incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1454947Aqueous solubility of the compound at pH 7.42018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1716322Antiviral activity against pseudovirus HIV-1 HXB-2 harboring Env M434I mutant infected in human U87.CD4.CXCR4 cells assessed as reduction in viral infection pretreated for 30 mins before viral infection and measured after 3 days by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1442786Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1442789Inhibition of CYP1A in human liver microsomes using ethoxyresorufin as substrate after 5 mins in presence of NADPH by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1442788Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate after 60 mins in presence of NADPH by LC-MS/MS analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID1716332Apparent permeability across basolateral to apical side in human Caco2 cells in presence of verapamil incubated for 2 hrs by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1454932Cytotoxicity against human Hep2 cells after 6 days by XTT assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1505615Inhibition of CYP2D6 (unknown origin)2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1866020Thermodynamic aqueous solubility of the compound2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
AID1454937Cytotoxicity against human SK-N-MC cells after 6 days by XTT assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1267276Metabolic stability in human liver microsomes assessed as compound remaining at 3 uM after 10 mins at pH 7.4 by LC/MS analysis2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Inhibitors of HIV-1 attachment: The discovery and structure-activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore.
AID1505630Antiviral activity against ENV pseudotyped CCR5-tropic HIV1 JFRL infected in human HeLa67 cells after 3 days by luciferase reporter gene assay2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1267274Antiviral activity against HIV-1 expressing JRFL envelope infected in human HeLa67 cells expressing CD4 and CCR5 receptors assessed as inhibition of luciferase activity after 3 days by single cycle pseudotype assay2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Inhibitors of HIV-1 attachment: The discovery and structure-activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore.
AID1716306Antiviral activity against clinical isolate HIV-1 92US657 infected in human PBMC cells assessed as reduction in viral transmission to TZM-bl cells pretreated for 1 hr before viral transmission and further incubated for 48 hrs by luciferase based assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1241769Antiviral activity against CXCR4-tropic HIV1 MN infected in human MT2 cells by monogram phenosense entry assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID1505614Inhibition of CYP2C9 (unknown origin)2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1505635Inhibition of [3H]BMS-488043 binding to HIV-1 JRFL gp120 after 1 hr by scintillation counting method2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1505607Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1454958Antiviral activity against HIV-1 isolate MN infected in human MT2 cells harboring CXCR4 co-receptor after 4 to 6 days2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1454940Protein binding in human serum2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1505605AUC in Sprague-Dawley rat at 5 mg/kg, po after 24 hrs2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1505613Inhibition of CYP2C19 (unknown origin)2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
AID1716330Efflux ratio for apparent permeability across basolateral to apical side to apical to basolateral side in human Caco2 cells incubated for 2 hrs by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1454942Cytotoxicity against human PBMC after 6 days by XTT assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1454964Antiviral activity against HIV-1 subtype C by p24 ELISA2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
AID1716329Apparent permeability across basolateral to apical side in human Caco2 cells incubated for 2 hrs by LC-MS/MS analysis2018European journal of medicinal chemistry, Jun-25, Volume: 154Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.
AID1454938Cytotoxicity against HOS cells after 6 days by XTT assay2018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's21 (75.00)24.3611
2020's7 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (10.71%)5.53%
Reviews3 (10.71%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (78.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]